TREATMENT WITH TERIPARATIDE MIGHT BE ASSOCIATED WITH CARDIOMETABOLIC CHANGES IN POSTMENOPAUSAL SEVERE OSTEOPOROTIC WOMEN

Parathormone (PTH) has been suggested to affect the cardiovascular system. Teriparatide (TPT), the hormonally active 1-34 fragment of PTH, provides an anabolic treatment for osteoporosis. The aim of the present study was to evaluate the cardiometabolic effects of 18-month treatment with 20 mu g/die teriparatide subcutaneosly. Fourteen women with postmenopausal severe osteoporosis treated with once-daily sc 20 mu g TPT (aged 67.6 +/- 2.5 years; BMI 27.7 +/- 1.0 kg/m(2)) and 24 age- and BMI-matched severe osteoporotic women treated with iv yearly 5 mg zoledronate (ZLN) were evaluated at baseline and at 12-18 months of treatment for anthropometric measures, calcium, glucose and lipid metabolic parameters, and assessment of cardiac geometry by conventional echocardiography. TPT was effective in increasing mean lumbar spine bone mineral density with no clinically relevant changes in calcium metabolism parameters. TPT patients experienced an increase of BMI (27.7 +/- 1.0 at baseline vs 29.0 +/- 1.0 kg/m(2) at last evaluation, P=0.005) and mean whole body fat percentage (37.0 +/- 2.1 vs 40.3 +/- 1.9%, P=0.05), associated with increased serum leptin levels (17.3 +/- 2.1 vs 22.9 +/- 3.0 ng/ml; P=0.049). Glucose and lipid parameters were not affected by TPT as well as by ZLN treatment. Furthermore, TPT was associated with a decrease in systolic blood pressure; a decrease in the fractional shortening (41.2 +/- 2.3 vs 36.9 +/- 1.2; P=0.05) and an increase in the relative wall thickness (0.39 +/- 0.01 vs 0.48 +/- 0.01 mm; P=0.002), suggestive for concentric cardiac remodeling, was detected by echocardiographic monitoring. These changes could not be detected in bone active drug-free age- and metabolic-matched controls. In conclusion, long-term TPT therapy might affect cardiometabolic and cardiac geometry parameters in severe osteoporotic women, though changes are not clinically relevant.